Solventum (SOLV) investor relations material

Executive summary

• Q2 2026 sales reached $2.21 billion, up 2.2% year-over-year, with 9.5% organic growth driven by strong execution, volume, and product mix, including advanced orders ahead of ERP cutovers.

• Transformation initiatives are progressing, with the final steps of 3M separation and ERP deployment nearly complete, reducing complexity and freeing resources for innovation and margin expansion.

• Announced intent to separate the Health Information Systems (HIS) business to sharpen MedTech focus and unlock shareholder value.

• Advanced $1 billion share repurchase program, with $288 million spent in Q2 and $355 million YTD.

• Net income for Q2 was $92 million, with diluted EPS at $0.53 GAAP and $2.55 non-GAAP.

Financial highlights

• Q2 gross margin was 60.1% (including a $100 million tariff refund), or 55.6% excluding the refund; adjusted operating margin was 28.4%, GAAP operating margin 8.2%.

• Free cash flow was $144 million, above expectations due to timing of tax payments and insurance proceeds.

• Operating income was $627 million (28.4% margin) on an adjusted basis; GAAP operating income was $181 million.

• Recognized $125 million in advanced customer orders and a $100 million pre-tax benefit from tariff refunds in Q2.

• Net debt was $4.7 billion; cash and equivalents were $403 million.

Outlook and guidance

• Raised 2026 organic sales growth guidance to 2.5%-3% (3.5%-4% ex-SKU exits).

• Adjusted EPS guidance increased to $7.10-$7.20, up from $6.40-$6.60, including $0.48 for tariff refund.

• Free cash flow guidance raised to $200-$300 million, with most expected in Q4.

• Operating margin outlook increased to 22.2%-22.7%.

• Q3 expected to see reversal of $125 million advanced order benefit from Q2.